83.37 USD
-2.09
2.45%
At close Jul 11, 4:00 PM EDT
After hours
83.40
+0.03
0.04%
1 day
-2.45%
5 days
0.64%
1 month
0.46%
3 months
26.05%
6 months
4.42%
Year to date
6.20%
1 year
-26.00%
5 years
-17.50%
10 years
306.68%
 

About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Employees: 10,300

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

21% more repeat investments, than reductions

Existing positions increased: 368 | Existing positions reduced: 303

19% more call options, than puts

Call options by funds: $401M | Put options by funds: $337M

0.11% more ownership

Funds ownership: 91.2% [Q4 2024] → 91.31% (+0.11%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]

4% less first-time investments, than exits

New positions opened: 109 | Existing positions closed: 113

2% less funds holding

Funds holding: 931 [Q4 2024] → 911 (-20) [Q1 2025]

12% less capital invested

Capital invested by funds: $27.7B [Q4 2024] → $24.3B (-$3.4B) [Q1 2025]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$90
8%
upside
Avg. target
$100
20%
upside
High target
$106
27%
upside

7 analyst ratings

positive
86%
neutral
14%
negative
0%
Truist Securities
Richard Newitter
22%upside
$102
Buy
Initiated
16 Jun 2025
Goldman Sachs
Kate McShane
25%upside
$104
Buy
Initiated
30 May 2025
Citigroup
Joanne Wuensch
22%upside
$102
Buy
Maintained
22 May 2025
Barclays
Matt Miksic
12%upside
$93
Equal-Weight
Maintained
5 May 2025
Canaccord Genuity
William Plovanic
27%upside
$106
Buy
Maintained
2 May 2025

Financial journalist opinion

Based on 11 articles about DXCM published over the past 30 days

Neutral
GlobeNewsWire
2 days ago
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
Positive
Kiplinger
3 days ago
The Best Growth Stocks to Buy
Growth stocks can create significant returns for investors, but what are they and how do you find the best ones? We take a closer look here.
The Best Growth Stocks to Buy
Positive
The Motley Fool
5 days ago
2 Stocks to Buy on the Dip and Hold for 10 Years
One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities.
2 Stocks to Buy on the Dip and Hold for 10 Years
Positive
Zacks Investment Research
1 week ago
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Positive
Zacks Investment Research
1 week ago
3 Reasons Growth Investors Will Love DexCom (DXCM)
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Growth Investors Will Love DexCom (DXCM)
Neutral
Investors Business Daily
1 week ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Neutral
Business Wire
1 week ago
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil.
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
Positive
Zacks Investment Research
2 weeks ago
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Positive
Zacks Investment Research
2 weeks ago
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Neutral
Zacks Investment Research
3 weeks ago
DXCM's Access Gains and Operational Strength Offset Margin Pressures
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
Charts implemented using Lightweight Charts™